Benchmark analyst Bill Sutherland lowered the firm’s price target on Quipt Home Medical (QIPT) to $4 from $6 and keeps a Buy rating on the shares after revenue missed expectations in fiscal Q2. On a positive note, Quipt continues to see no negative impact from GLP-1 medications on demand for sleep therapy set ups and supplies, like other respiratory-focused home medical equipment companies, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical: Resilience and Growth Potential Amidst Challenges
- Quipt Home Medical downgraded to Hold from Buy at Canaccord (yesterday)
- Quipt Home Medical downgraded to Hold from Buy at Canaccord
- Quipt Home Medical: Strategic Initiatives and Financial Resilience Amidst Revenue Challenges
- Quipt Home Medical Reports Q2 2025 Results Amid Revenue Challenges